within Pharmacolibrary.Drugs.ATC.N;

model N06AX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.075,
    adminDuration  = 600,
    adminMass      = 0.03,
    adminCount     = 1,
    Vd             = 0.1,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00105,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Mianserin is a tetracyclic antidepressant that acts mainly as a noradrenergic and specific serotonergic antidepressant (NaSSA). It is approved in several countries for the treatment of major depressive disorder, but is not approved for use in the United States. It is also used off-label for insomnia and anxiety disorders in some regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li>M Shami, H L Elliott, A W Kelman, B Whiting,The pharmacokinetics of mianserin.,British journal of clinical pharmacology,1983<a href='https://pubmed.ncbi.nlm.nih.gov/6824562/'>https://pubmed.ncbi.nlm.nih.gov/6824562/</a></li><li>Shuichi Nawata, Noriko Kohyama, Naoki Uchida, Satoshi Numazawa, Masayuki Ohbayashi, Yasuna Kobayashi, Masanori Iwata, Takanori Nakajima, Hiroshi Saito, Akira Izuka, Toshinori Yamamoto,The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study.,Journal of pharmaceutical health care and sciences,2016<a href='https://pubmed.ncbi.nlm.nih.gov/27190632/'>https://pubmed.ncbi.nlm.nih.gov/27190632/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06AX03;
